All In Biotech

Drug Trial Radar · NCT03934567

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Oral Histone Deacetylase (HDAC)-Inhibitor Abexinostat, as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (FL)

Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

87

Actual

Start

Apr 22, 2020

Primary completion

Jan 29, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
Xynomic Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (FL)

Conditions

  • Lymphoma, Follicular

Interventions

  • AbexinostatDrug

    Abexinostat tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical effect of abexinostat on objective response rate as assessed by an independent central imaging reviewTime frame: up to 56 days

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • China-Japan Friendship Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Jilin Cancer Hospital

    Changchun, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Cancer Center of Guangzhou Medical University

    Guangzhou, China

  • Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University

    Guangzhou, China

  • Nanfang Hospital

    Guangzhou, China

  • Hainan General Hospital

    Hainan, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medical

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • The Affiliated Tumor Hospital of Harbin Medical University

    Harbin, China

  • The First Hospital of Lanzhou University

    Lanzhou, China

  • Linyi Cancer Hospital

    Linyi, China

  • Nantong Tumor Hospital

    Nantong, China

  • Shanghai Sixth people's hospital

    Shanghai, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • The Forth Hospital of Hebei Medical University

    Shijiazhuang, China

  • Tianjin People's Hospital

    Tianjin, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.